---
title: "Lakeside Holding Ltd 3Q 2026: Revenue $1.33M, Net income $142K — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286969064.md"
description: "Lakeside Holding Ltd reported Q3 2026 revenue of $1.33M, a 167% increase from $497K YoY, and net income of $142K, reversing a $1.071M loss from the previous year. Pharmaceutical sales surged 614% year-to-date, with active customers rising from 8 to 14. Infusion products accounted for 93% of sales, though gross margin declined. The company reclassified ABL Chicago as discontinued operations to focus on pharmaceutical distribution."
datetime: "2026-05-19T21:21:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286969064.md)
  - [en](https://longbridge.com/en/news/286969064.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286969064.md)
---

# Lakeside Holding Ltd 3Q 2026: Revenue $1.33M, Net income $142K — 10-Q Summary

Lakeside Holding Ltd reported third-quarter 2026 results showing a sharp year-over-year improvement as revenue rose to $1.33M and the company turned profitable with net income of $142K, compared with $497K revenue and a $1.071M loss in the year‑ago quarter.

**Financial Highlights**

-   Revenue was $1.33M for Q3 2026, up from $497K in the year‑ago quarter; YoY change 167.0%.
-   Net income was $142K for Q3 2026, versus a net loss of $1.071M in the year‑ago quarter (turned profitable YoY).

**Business Highlights**

-   Pharmaceutical revenue growth accelerated, with continuing pharmaceutical sales up roughly 614% year to date, driven by expansion of infusion products and new customers.
-   Active customers increased from 8 to 14 over the nine‑month period; sales are primarily to hospitals and distributors through agents, lifting order volumes.
-   Infusion products comprised about 93% of sales; gross margin declined due to reduced supplier rebates despite higher volumes.
-   The company disposed of ABL Chicago on Feb. 12, 2026, reclassifying it as discontinued operations to concentrate on pharmaceutical distribution growth.
-   Working capital and liquidity were affected by a large third‑party loan receivable and higher prepayments, concentrating current assets and impacting operating cash flow.

Original SEC Filing: Lakeside Holding Ltd \[ LSH \] - 10-Q - May. 19, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [LSH.US](https://longbridge.com/en/quote/LSH.US.md)
- [XPH.US](https://longbridge.com/en/quote/XPH.US.md)
- [PPH.US](https://longbridge.com/en/quote/PPH.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [PJP.US](https://longbridge.com/en/quote/PJP.US.md)

## Related News & Research

- [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Ultragenyx Shareholders Approve Incentive Plan, Elect Directors](https://longbridge.com/en/news/286809118.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)